Top Markets
#1 Nesa Nesa +797.03%
#2 Cortex Cortex +68.91%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.76%
#4 QuantixAI QuantixAI +40.81%
#5 Pons Pons +25.08%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +20.00%
#8 Renzo Restaked LST Renzo Restaked LST +10.38%
#9 Fartcoin Fartcoin +9.77%
#10 PondCoin PondCoin +8.97%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Classement en actions #19672
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Prix de l'action
$3.49
Dernière synchronisation: 2022-08-12
Capitalisation boursière
$154.10M
Changement (1 jour)
12.28%
Changement (1 an)
0.00%
Pays
DE
Échange InflaRx N.V. (IF0)

Catégorie

Healthcare
Nombre d'actions en circulation pour InflaRx N.V. (IF0)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de InflaRx N.V., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de InflaRx N.V. (IF0) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH